Blood test using cfDNA fragment patterns to tell if a lung nodule is cancer
Official title: A Prospective Clinical Study Evaluating the Noninvasive Use of Circulating Cell-Free DNA Fragmentomics to Differentiate Benign and Malignant Lung Nodules, With Emphasis on Small Nodules.
Run by Shanghai Chest Hospital · NCT07399210 · Data updated 2026-11-12
This project will see if a blood test that analyzes cfDNA fragments can tell adults with CT-detected lung nodules whether the nodules are benign or malignant.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 240 (estimated) |
| Sponsor | Shanghai Chest Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | August 21, 2024 |
| Main results expected | August 21, 2026 |
| Study ends | August 21, 2026 |
| Registry record updated | February 10, 2026 |
| Trial ID | NCT07399210 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with CT-detected lung nodules that meet the study's size criteria, who can provide a 5 mL blood sample and have nodule status clinically confirmed without recent cancer-directed therapy, are ideal candidates.
✕Probably not a fit
People who are pregnant or breastfeeding, have had a recent (within 5 years) other malignancy, have severe comorbid organ disease, have nodules outside the specified size ranges, or cannot provide a pre-treatment blood sample are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study collects a 5 mL peripheral blood sample from adults with imaging-detected lung nodules and analyzes cell-free DNA fragmentomics to look for patterns that differ between benign and malignant nodules. Eligible nodules must meet specified size criteria and the nodule status must be clinically confirmed; participants should not have had cancer-directed therapy in the prior three months. No interventions are assigned; researchers will compare fragmentomic signatures between confirmed benign and malignant cases to determine diagnostic accuracy. All enrollment and sample collection are conducted at Shanghai Chest Hospital.
Why it matters
Potential benefit: If successful, the test could provide a noninvasive blood-based way to help decide which lung nodules need biopsy or surgery, potentially reducing unnecessary invasive procedures.
How similar studies have gone: Early research on cfDNA fragmentomics has shown promising results for detecting cancer-related signals in blood, but the approach remains experimental and is not yet standard clinical practice.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years; * Positive for lung nodules on low-dose spiral CT (LDCT) meeting one of the following criteria: Solid or part-solid nodules ≥ 5 mm and ≤ 20 mm; Pure ground-glass nodules ≥ 8 mm and ≤ 30 mm; In cases of multiple nodules, the largest nodule (by maximum diameter) must meet these criteria; * Participants whose lung nodule status (benign or malignant) can be clinically confirmed; * No cancer-directed therapy (e.g., chemotherapy, radiotherapy, immunotherapy, cell therapy) within the past 3 months; * Able to provide a 5 mL peripheral blood sample prior to any treatment; * Voluntary signing of informed consent after full explanation of the study. Exclusion Criteria: * Pregnant or breastfeeding; * Current or past diagnosis (within the past 5 years) of malignant tumors (excluding patients with early-stage lung cancer who have undergone surgery but still have multiple evaluable nodules), or with severe heart disease, serious liver or kidney disorders, or significant bone marrow hematopoietic dysfunction; * History of organ transplantation or blood transfusion within the past 3 months; * History of seropositivity for human immunodeficiency virus (HIV); * Any other condition deemed inappropriate for study participation by the investigators.
Where it's running
-
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Xuan Wang
- Email: dst.ding@gmail.com
- Phone: +8613524594847
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Boosting lung cancer screening for patients seen in the emergency department
This project will test whether giving eligible emergency department patients a facilitated referral plus text reminders helps more people get lung cancer screening.
-
Risk-based lung cancer screening in COPD patients using ML and clinical models
This study tests whether a PLCOm2012 risk model plus a machine learning model can spot COPD patients at high risk for lung cancer to see if they benefit from low-dose CT screening.
-
AI-Personalized Discharge Education After Lung Cancer Surgery
This study tests whether an AI-generated, personalized discharge guide helps patients recover better after lung cancer surgery compared with standard discharge education.
-
Next Generation Delivery System (NGDS) for SBRT in thorax and upper abdomen
A study tests a new machine to deliver SBRT more quickly and comfortably for adults with thoracic or upper abdominal cancers.
-
Low-Intensity Endurance Exercise to Help Lung Cancer-Related Fatigue
This trial tests whether light, regular endurance exercise can help reduce fatigue and improve quality of life for people with lung cancer in addition to their usual care.
-
Low-Intensity Endurance Exercise for Lung Cancer-Related Fatigue
A randomized trial tests whether light, regular endurance exercise can help reduce fatigue and improve quality of life for people with lung cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.